Stock Symbol:   

Stoxline Mobile
Home  |  Stock Charts  |  Showcases  |  Stock Ranks  |  Options  |  ETFs  |  Educations  |  Forex Crypto

Antares Pharma, Inc. (ATRS)

5.59   0.01 (0.18%) 12-31 19:00
Open: 5.585 Pre. Close: 5.58
High: 5.59 Low: 5.58
Volume: 1,763,417 Market Cap: 0(M)

Technical analysis

as of: 2022-11-18 4:18:46 PM
Stoxline posted a NEUTRAL today, same as yesterday. Current trend continues, but could change at anytime. It is not a good time to buy or sell.
Target: Six months: 6.52     One year: 7.62
Support: Support1: 5.58    Support2: 5.57
Resistance: Resistance1: 5.59    Resistance2: 6.52
Pivot: 5.59
Moving Average: MA(5): 5.59     MA(20): 5.59
MA(100): 5.59     MA(250): 4.81
MACD: MACD(12,26): 0     Signal(9): 0
Stochastic oscillator: %K(14,3): 100     %D(3): 100
RSI: RSI(14): 78.6
52-week: High: 5.59  Low: 3.1
Average Vol(K): 3-Month: 1,763 (K)  10-Days: 1,763 (K)

Price, moving averages and Bollinger Bands

Price has closed below its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and NEUTRAL in mid-long term.
[ ATRS ] has closed Bollinger Bands are 0% narrower than normal.

Stock Price Prediction

Update at 5:00pm EST
If tomorrow: Open lower Open higher
High: 5.6 - 5.62 5.62 - 5.65
Low: 5.51 - 5.55 5.55 - 5.57
Close: 5.54 - 5.59 5.59 - 5.63

Company Description

Antares Pharma, Inc., a specialty pharmaceutical company, focuses primarily on the development and commercialization of pharmaceutical products and technologies that address patient needs in targeted therapeutic areas. It develops, manufactures, and commercializes novel therapeutic products using its drug delivery systems. The company's injection products include XYOSTED for subcutaneous administration of testosterone replacement therapy in adult males; OTREXUP a subcutaneous methotrexate injection indicated for adults with severe active rheumatoid arthritis, children with active polyarticular juvenile idiopathic arthritis, and adults with severe recalcitrant psoriasis; and NOCDURNA sublingual tablets indicated for the treatment of nocturia due to nocturnal polyuria in adults who awaken at least two times per night to urinate. Its injection products also comprise generic Epinephrine Injection USP products indicated for emergency treatment of severe allergic reactions, including anaphylaxis in adults and certain pediatric patients; Sumatriptan Injection USP indicated for the acute treatment of migraine headaches and cluster headache in adults; and Makena subcutaneous auto-injector drug-device combination product indicated to reduce the risk of preterm birth in women, as well as Teriparatide injection used for the treatment of osteoporosis in postmenopausal women and men at increased risk of fracture, and glucocorticoid induced osteoporosis in men and women. In addition, the company develops disposable pen injectors for diabetes and osteoporosis; QuickShot auto-injectors; TLANDO to treat deficiency or absence of endogenous testosterone in adult males; and drug/device products for urologic oncology, immunology, and endocrinology. The company has strategic alliances and partnerships with Pfizer Inc., Idorsia Pharmaceuticals Ltd, Teva Pharmaceutical Industries, Ltd, and AMAG. Antares Pharma, Inc. was incorporated in 1979 and is headquartered in Ewing, New Jersey. As of May 23, 2022, Antares Pharma, Inc. operates as a subsidiary of Halozyme Therapeutics, Inc.

Headline News

Mon, 27 Mar 2023
Adrenal Crisis Market Report 2032: Epidemiology Data, Pipeline ... - Digital Journal

Tue, 08 Nov 2022
HALOZYME THERAPEUTICS, INC. Management's Discussion and Analysis of Financial Condition and Results of Operations (form 10-Q) -

Tue, 24 May 2022
Halozyme Completes Antares Pharma Acquisition - PR Newswire

Tue, 26 Apr 2022

Wed, 13 Apr 2022
Halozyme Buys Antares In $960M Deal To Create One Drug Delivery, Specialty Product Entity - Yahoo Finance

Wed, 13 Apr 2022
Antares Pharma Stock Soars After $960 Million Halozyme Buyout - Barron's

Financial Analysis

Price to Book Value: Outperform
P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly.
Price to Earnings: Underperform
PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS).
Discounted cash flow: Outperform
DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows.
Return on Assets: Neutral
ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit.
Return on Equity: Neutral
ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency.
Debt to Equity: Neutral
evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn.
Free Technical Analysis Charts

Stock Basics & Statistics

Exchange:  NASDAQ
Sector:  Healthcare
Industry:  Medical Instruments & Supplies
Shares Out. 171 (M)
Shares Float 134 (M)
% Held by Insiders 7.5 (%)
% Held by Institutions 62.8 (%)
Shares Short 4,780 (K)
Shares Short P.Month 3,910 (K)

Stock Financials

EPS 0.23
EPS Est Next Qtl -0.03
EPS Est This Year -0.11
EPS Est Next Year 0
Book Value (p.s.) 1.02
Profit Margin (%) 21.8
Operating Margin (%) 10.4
Return on Assets (ttm) 5
Return on Equity (ttm) 26.6
Qtrly Rev. Growth -1.3
Gross Profit (p.s.) 0.67
Sales Per Share 1.07
EBITDA (p.s.) 0.13
Qtrly Earnings Growth 0
Operating Cash Flow 30 (M)
Levered Free Cash Flow -20 (M)

Stock Valuations

PE Ratio 24.3
PEG Ratio 0.8
Price to Book value 5.42
Price to Sales 5.2
Price to Cash Flow 32.09

Stock Dividends

Dividend 0
Forward Dividend 0
Dividend Yield 0%
Dividend Pay Date Invalid DateTime.
Ex-Dividend Date Invalid DateTime.
Your Ad Here
StockChart iOS
StoxlineLite iOS
StoxlineLite iOS
OptionCalc iOS
StockChart Android
StoxlineLite Android
StoxlinePro Android
OptionCalc Android
(c) 2006-2022 | Contact us           
Data and information is provided for informational purposes only, and is not intended for trading purposes. Neither nor its data provider shall be liable for any errors or delays in the content, or for any actions taken in reliance thereon. By accessing the web site, a user agrees not to redistribute the information found therein.